This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-29 and is reviewed periodically as new material appears.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
== Evolution == Most of the aaRSs of a given specificity are evolutionarily closer to one another than to aaRSs of another specificity. However, AsnRS and GlnRS group within AspRS and GluRS, respectively. Most of the aaRSs of a given specificity also belong to a single class. However, there are two distinct versions of the LysRS - one belonging to the class I family and the other belonging to the class II family. The molecular phylogenies of aaRSs are often not consistent with accepted organismal phylogenies. That is, they violate the so-called canonical phylogenetic pattern shown by most other enzymes for the three domains of life - Archaea, Bacteria, and Eukarya. Furthermore, the phylogenies inferred for aaRSs of different amino acids often do not agree with one another. In addition, aaRS paralogs within the same species show a high degree of divergence between them. These are clear indications that horizontal transfer has occurred several times during the evolutionary history of aaRSs. A widespread belief in the evolutionary stability of this superfamily, meaning that every organism has all the aaRSs for their corresponding amino acids, is misconceived. A large-scale genomic analysis on ~2500 prokaryotic genomes showed that many of them miss one or more aaRS genes whereas many genomes have 1 or more paralogs. AlaRS, GlyRS, LeuRS, IleRS and ValRS are the most evolutionarily stable members of the family. GluRS, LysRS and CysRS often have paralogs, whereas AsnRS, GlnRS, PylRS and SepRS are often absent from many genomes.
== Poiseuille flow in a pipe with an oscillating pressure gradient == Flow through pipes with an oscillating pressure gradient finds applications in blood flow through large arteries. The imposed pressure gradient is given by
=== Cancer === Water-soluble polymer shells are being created to deliver a protein, apoptin, into cancer cells. The protein goes into the nucleus of the cancer cells while leaving healthy cells alone, unlike other conventional therapies as gene therapies and chemotherapy. The capsules are 100 nm in size. Active targeting of cancer cells is also being researched. Through active targeting, the nanocapsules form ligands that bind to malignant cells for cell delivery. This method is especially beneficial for those drugs that are not as permeable through the cell membrane, and where tissues are diseased, the nanoparticles are able to bond easier with the malignant cells.
=== Pharmacogenetics === The dihydropyrimidine dehydrogenase (DPD) enzyme is responsible for the detoxifying metabolism of fluoropyrimidines, a class of drugs that includes 5-fluorouracil, capecitabine, and tegafur. Genetic variations within the DPD gene (DPYD) can lead to reduced or absent DPD activity, and individuals who are heterozygous or homozygous for these variations may have partial or complete DPD deficiency; an estimated 0.2% of individuals have complete DPD deficiency. Those with partial or complete DPD deficiency have a significantly increased risk of severe or even fatal drug toxicities when treated with fluoropyrimidines; examples of toxicities include myelosuppression, neurotoxicity and hand-foot syndrome.
In 1992, whilst studying for his PhD, he also ran the London Marathon, in a time of 4 hours and 41 minutes, to raise money to buy a computer for a young boy with physical disabilities. Skinner's PhD involved developing genetic tests to detect congenital adrenal hyperplasia in children. He had work published in a number of scientific journals. In 1994 he had his work published in Human Molecular Genetics. In 1994, Skinner married Dr. Monica Schneider (also a molecular biologist), and in 1996 their son James was born. From 1994 to 1996 Skinner worked as a Post-Doctoral Research Fellow at Vanderbilt University Medical Center, in Nashville, Tennessee. The work he carried out there involved gene sequencing and protein purification of cytochrome P450 enzymes. His work was published in the Journal of Biological Chemistry. From 1996 to 1997 Skinner took care of his infant son, James, whilst his wife continued to work at Vanderbilt University Medical Center.
Sources: en.wikipedia.org
Xylazine binds at a ratio of 160:0, the lowest of all α2-adrenergic receptor agonists and 1/10th of that of medetomidine and dexmedotimidine. Xylazine is less selective than the other α2-Adrenergic receptor agonists. The analgesic effect of xylazine comes from binding to receptors at the substantia gelatinosa and locus coeruleus.
Director, Chuckling Goat. For services to Charity and to Innovation in Wales. Evelyn Mary Joy. Agent, Buckingham Conservative Association. For Political and Public Service. James Michael Keggen. Coxswain, Port St Mary Lifeboat Station, Royal National Lifeboat Institution. For voluntary services to Maritime Safety. Sharon Elaine Kelly. Project Manager, Royston Youth Action. For services to Young People. Lindsey Kemp. Officer, National Crime Agency. For services to Law Enforcement. Maurice Joseph Kennedy. Volunteer, Transport Training Board. For services to the Transport and Logistics Industries of Northern Ireland and Great Britain. Christine Anne Kenyon. Deputy Principal, The Manchester College, Greater Manchester. For services to Further Education. Michael Kettle. Explosives Officer, Metropolitan Police Service. For services to Bomb Disposal. Helen Morag Keys. Entrepreneur, Queen's University's Students' Union. For services to Entrepreneurship and Innovation in Farming. Jasdeep Hari Bhajan Singh Khalsa. Founder, The Sikher Project. For charitable services to the Sikh Community. Professor Saye Hock Khoo. Professor of Pharmacology and Therapeutics, University of Liverpool. For services to Infectious Diseases and Pharmacology. Virginia Kiddle. Officer, National Crime Agency. For services to Law Enforcement. Amy Kilby. UK Representative, International Project Management Organisation. For services to Military Communications. James Kilpatrick. Chair, RVH Liver Support Group. For services to People with Liver Disease and their Carers in Northern Ireland. Charline Zephoria King.
=== Macroscopic examination === Visual examination of the specimen may provide information to the pathologist or the physician. For example, fluid drained from an abscess may appear cloudy, or cerebrospinal fluid obtained by lumbar puncture may exhibit xanthochromia, suggesting a bleed has occurred. Laboratory technologists may provide qualitative descriptions accordingly.
== Atom economy == The advantage in atom economy of using NCAs for peptide formation is that there is no need for a protecting group on the functional group reacted with the amino acid. For example, the Merrifield synthesis depends on the use of Boc and Bzl protecting groups, which need be removed after the reaction. In the case of Bailey peptide synthesis, the free peptide is directly obtained after the reaction. However, unwanted and difficult to remove by-products may be formed. An N-substitution of the NCA (for example, by an o-nitrophenylsulfenyl group) can simplify the subsequent purification process, but on the other hand deteriorates the atom economy of the reaction. The synthesis of NCAs can be carried out by the Leuchs reaction or by the reaction of N-(benzyloxycarbonyl)-amino acids with oxalyl chloride. In the latter case, again the procedure is less efficient in the sense of atom economy.
An additional study published in 2020 by Woodward and colleagues, for the journal Science Advances indicates that during their growth from juvenile to adult, Tyrannosaurus was capable of slowing down its growth to counter environmental factors such as lack of food. Based on BMRP 2002.4.1 and BMRP 2006.4.4 between 13 and 15 years old housed at the Burpee Museum in Illinois then referred to as juvenile Tyrannosaurus specimens, the authors suggested that the rate of maturation for Tyrannosaurus was dependent on resource abundance. This study also indicates that in such changing environments, Tyrannosaurus was particularly well-suited to an environment that shifted yearly in regards to resource abundance, hinting that other midsize predators might have had difficulty surviving in such harsh conditions and explaining the niche partitioning between juvenile and adult tyrannosaurs. The study further suggested that Tyrannosaurus and Nanotyrannus are synonymous, due to analysis of the growth rings in the bones of the two specimens studied. In January 2026, Woodward, Myhrvold and Horner performed a comprehensive histological analysis of 17 tyrannosaur specimens, and argued that Tyrannosaurus likely experienced a more gradual annual growth rate slope than indicated by earlier studies and evidence of a protracted subadult stage, reaching asymptotic size at around 35–40 years of age. The upper limit of the annual growth rate estimate is approximately 43–53 years.
Sources: en.wikipedia.org
More than 1 in 2 people with OI also have dentinogenesis imperfecta (DI)—a congenital abnormality in the formation of dentin, one of the four major components of the human tooth. Dental treatment may pose a challenge as a result of the various deformities, skeletal and dental, due to OI. Children with OI should go for a dental check-up as soon as their teeth erupt; this may minimize tooth structure loss as a result of abnormal dentine, and they should be monitored regularly to preserve their teeth and oral health. Many people with OI are treated with bisphosphonates, and there are several possible related complications with dental procedures, for example, medication-related osteonecrosis of the jaw (MRONJ). However, no report of bisphosphonate-related MRONJ in either a child or adult with OI was found in a 2016 Cochrane review of the safety and efficacy of bisphosphonates for OI.
== References == Courtnall, Roy; Johnson, Chris (1999). The Art of Violin Making. London: Robert Hale. ISBN 0-7090-5876-4. Patrick Spielman. Gluing and Clamping: A Woodworker's Handbook. Sterling Publishing, 1986. ISBN 0-8069-6274-7 Weisshaar, Hans; Shipman, Margaret (1988). Violin Restoration. Los Angeles: Weisshaar~Shipman. ISBN 0-9621861-0-4.
Educational resource materials (including animations) by the American Society for Bone and Mineral Research Review (including references) of piezoelectricity and bone remodelling A good basic overview of bone biology from the Science Creative Quarterly Bone histology photomicrographs Archived 6 July 2020 at the Wayback Machine
=== Cellulose casings === Cellulose, usually from cotton linters or wood pulp, is processed to make viscose, which is then extruded into clear, tough casings for making wieners and franks. They also are shirred for easier use and can be treated with dye to make "red hots". The casing is peeled off after cooking, resulting in "skinless" franks. Cellulosic viscose solutions are combined with wood or for example abacá pulp to make large diameter fibrous casings for bologna, cotto salami, smoked ham and other products sliced for sandwiches. This type is also permeable to smoke and water vapor. They can be flat or shirred, depending on application, and can be pretreated with smoke, caramel color, or other surface treatments.
=== Collagen synthesis === An injury does not become a scar until the wound has completely healed; this can take many months, or years in the worst pathological cases, such as keloids. To begin to patch the damage, a clot is created; this clot is the beginning process that results in a provisional matrix. In the process, the first layer is a provisional matrix and is not a scar. Over time, the wounded body tissue overexpresses collagen inside the provisional matrix to create a collagen matrix. This collagen overexpression continues and crosslinks the fiber arrangement inside the collagen matrix, making the collagen dense. This densely packed collagen, morphing into an inelastic whitish collagen scar wall, blocks off cell communication and regeneration; as a result, the new tissue generated will have a different texture and quality than the surrounding unwounded tissue. This prolonged collagen-producing process results in a fortuna scar.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.